US Stock Insider Trading | Wanda Biopharmaceuticals disclosed details of five insider transactions on March 4

K-LinePoet · 2026-03-31T11:18:18+00:00

Wanda Biopharmaceuticals disclosed five insider transactions, with Director Polymeropoulos selling 156,200 shares on March 2, 2026, for a total of $1,277,000. Other executives also sold shares on the same day, indicating the trading activity of the company's management.

K-LinePoet

2026-03-31 11:18:18

Abstract generation in progress

On March 4, 2026, Vanda BioPharma (VNDA) disclosed five transactions by company insiders. Director Polymeropoulos Mihael Hristos sold 156,200 shares on March 2, 2026.

[Recent Insider Trading]

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Transaction Price/US$	Total Amount/US$
March 4, 2026	Executive	Williams Timothy	March 2, 2026	Sell	42,400	8.27	350,800
March 4, 2026	Executive	Birznieks Gunther	March 2, 2026	Sell	42,400	8.27	350,700
March 4, 2026	Executive	Moran Kevin Patrick	March 2, 2026	Sell	42,400	8.27	350,800
March 4, 2026	Executive	Wijkstrom Joakim	March 2, 2026	Sell	30,800	8.27	254,600
March 4, 2026	Director	Polymeropoulos Mihael Hristos	March 2, 2026	Sell	156,200	8.17	1,277,000
February 24, 2026	Director	Honore Tage	February 23, 2026	Sell	30,000	8.03	240,900
August 8, 2025	Director	Polymeropoulos Mihael Hristos	August 7, 2025	Buy	10,000	4.15	41,500
June 16, 2025	Director	Mitchell Stephen Ray	June 13, 2025	Sell	7000	4.59	321,300
May 21, 2025	Director	Polymeropoulos Mihael Hristos	May 21, 2025	Buy	481	4.39	2,111.59
May 21, 2025	Director	Polymeropoulos Mihael Hristos	May 21, 2025	Buy	9519	4.40	41,900

[Company Profile]

Vanda Pharmaceuticals Inc. was incorporated in Delaware in 2002. The company is a global leader in biopharmaceuticals, focused on the development and commercialization of innovative therapies to address highly unmet medical needs and improve patients’ lives. The company works to advance new approaches by bringing important new drugs to market through responsible innovation. The company is committed to using technologies that support sound science in drug discovery, clinical trials, and the commercial positioning of products, including genetics and genomics.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes